Zydus Lifesciences Ltd

Past performance
Performance overview
Zydus Lifesciences Ltd
About Zydus Lifesciences Ltd Zydus Lifesciences Ltd., formerly Cadila Healthcare Ltd., is a prominent Indian pharmaceutical company engaged in R&D, manufacturing, marketing, and sales across the pharmaceutical value chain. It offers human formulations, active pharmaceutical ingredients (APIs), animal healthcare, and consumer wellness products, including biosimilars and vaccines. With manufacturing facilities in several Indian states, Zydus has expanded its global footprint through strategic acquisitions and alliances, including partnerships with companies like Bayer, Gilead Sciences, and Takeda Pharmaceutical. The company has a strong presence in the US generics market, launching numerous products and expanding its portfolio with strategic acquisitions, such as Sentynl Therapeutics in the pain management segment. Zydus has made significant strides in biosimilar and specialty drug development, notably launching Exemptia, the first biosimilar of Adalimumab. The company also engages in collaborative research to tackle global health challenges like malaria and chikungunya. With a robust pipeline and continuous innovation, Zydus Lifesciences remains a key player in the global pharmaceutical landscape.
Website zyduscadila.com
Founded 1995
Headquarters Ahmedabad